Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 297

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

Open access
André, Thierry, Meyerhardt, Jeffrey, Iveson, Timothy, Sobrero, Alberto, Yoshino, Takayuki, Souglakos, Ioannis, Grothey, Axel, Niedzwiecki, Donna, Saunders, Mark, Labianca, Roberto, Yamanaka, Takeharu, Boukovinas, Ioannis, Vernerey, Dewi, Meyers, Jeffrey, Harkin, Andrea, Torri, Valter, Oki, Eiji, Georgoulias, Vassilis, Taieb, Julien, Shields, Anthony, Shi, Qian·2020·The Lancet Oncology

Abstract

Summary Background: A prospective, pooled analysis of six randomized phase 3 trials was performed to evaluate disease-free survival regarding non-inferiority (NI) of three versus six months of adjuvant chemotherapy for stage III colon cancers. NI was not demonstrated. We now report the final overall survival results. Methods: Patients with age ≥18 years and performance score of 0-1 accrued from June 2007 to December 2015 across 12 countries in CALGB/SWOG80702, IDEA France, SCOT, ACHIEVE, TOSCA, and HORG trials (sample sizes: 708 to 3,983), who started any treatment (modified intent-to-treat) were included. Fluoropyrimidine and oxaliplatin with 5-FU/folinic acid (FOLFOX) or capecitabine (CAPOX) were delivered every 2 and 3 weeks, respectively. The primary endpoint was disease-free survival (time to relapse, secondary colorectal primary tumor, or death due to all causes) and that overall survival (time to death due to all causes) was the prespecified secondary endpoint. The overall survival NI margin was set to be HR=1·11. Pre-planned sub-group analyses included regimen and risk group. NI was to be declared if the one-sided false discovery rate adjusted (FDRadj) p-value was <0·025. Findings: With median follow-up of 72 months (IQR, 72·2-72·5), 2584 deaths among 12,835 patients were observed. Of all patients, 39·5% received CAPOX and 60·5% FOLFOX. Comparing three versus six months, the five-year overall survival rate was 82·4% and 82·8%, with an estimated hazard ratio (HR) of 1·02 (95% confidence interval [CI], 0·95-1·11; NI FDRadj p, 0·058); five-year overall survival rate was 82·1% versus 81·2% with an estimated HR of 0·96 (95% CI, 0·85-1·08; NI FDRadj p, 0·033) for CAPOX and 82·6% and 83·8%, estimated HR of 1·07 (95% CI, 0·97-1·18; NI FDRadj p, 0·34) for FOLFOX. Updated disease-free survival results confirmed previous findings. Adverse events data were not updated. Conclusions: While NI for overall survival could not be confirmed after multiplicity adjustment, the absolute 0·4% difference in five-year overall survival should be placed in clinical context. Overall survival results support the use of 3 months of adjuvant CAPOX for the vast majority of stage III colon cancer patients. This conclusion is strengthened by the substantial reduction of toxicities, inconveniencies, and cost associated with a shorter treatment duration. Funding: IDEA analyses were supported by a grant of U10 CA180882 from the National Cancer Institute.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(20)30527-1

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 297

Metadata

Authors
André, T., Meyerhardt, J., Iveson, T., Sobrero, A., Yoshino, T., Souglakos, I., Grothey, A., Niedzwiecki, D., Saunders, M., Labianca, R., Yamanaka, T., Boukovinas, I., Vernerey, D., Meyers, J., Harkin, A., Torri, V., Oki, E., Georgoulias, V., Taieb, J., Shields, A., & Shi, Q.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2020-12
Volume
21
Issue
12
Pages
1620-1629
ISSN
1470-2045 (ISSN-L)
OpenAlex
W3110292103
Cited by
297
References
4
FWCI
12.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. https://app.cochat.ai/papers/10.1016/s1470-2045(20)30527-1
The paper
André, T., Meyerhardt, J., Iveson, T., Sobrero, A., Yoshino, T., Souglakos, I., Grothey, A., Niedzwiecki, D., Saunders, M., Labianca, R., Yamanaka, T., Boukovinas, I., Vernerey, D., Meyers, J., Harkin, A., Torri, V., Oki, E., Georgoulias, V., Taieb, J., . . . Shi, Q. (2020). Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30527-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.